polidocanol and Liver-Diseases

We evaluated our initial experience of performing sclerotherapy for symptomatic hepatic cysts using polidocanol foam instead of a liquid sclerosant.. Three consecutively registered patients with symptomatic hepatic cysts (one with polycystic liver disease) underwent polidocanol foam sclerotherapy. A pigtail catheter was inserted into the targeted cyst following percutaneous cyst puncture under ultrasound guidance, and the cyst fluid was aspirated. To confirm the absence of communications between the cyst and surrounding hepatic vessels, 3 % polidocanol foam sclerosant was injected at a 1:4 ratio of polidocanol to air following digital subtraction cystography with carbon dioxide. C-arm computed tomography (CT) guidance also was used to monitor foam filling of the targeted cyst. The maximum dose of sclerosant injected per treatment session did not exceed 10 ml. The catheter was kept unclamped overnight for open drainage, and additional sclerotherapy sessions were performed on subsequent days, if needed.. Efficient sclerotherapy was achieved with an average of two sessions. The initial mean cyst volume was 1,052 ml, and gradual resolution was observed without recurrence. The mean reduction rate was 97.9 % (97.7-98.3 %), and all cyst-associated symptoms disappeared. The median follow-up period was 17 (range 6-21) months. Although one patient experienced moderate-grade fever and another moderate pain at the puncture site, no major complications were observed.. Polidocanol foam sclerotherapy is a safe and effective treatment for symptomatic hepatic cysts.

Topics: Aged; Carbon Dioxide; Cysts; Female; Humans; Liver Diseases; Magnetic Resonance Imaging, Interventional; Male; Polidocanol; Polyethylene Glycols; Punctures; Radiography, Interventional; Sclerosing Solutions; Sclerotherapy; Tomography, X-Ray Computed; Treatment Outcome

Hepatic cysts have a prevalence of 2.5-7% and most of them are asymptomatic. However, large cysts may cause complaints; in such cases an appropriate treatment is necessary (open surgery, laparoscopic deroofing, removal of cystic fluid and injection of a sclerosing agent. The aim of this study was to assess the efficacy and safety of a single session technique with polidocanol in the therapy of symptomatic non parasitic hepatic cysts. MATERIAL AND METHODS. The study included 13 patients with symptomatic liver cysts (range 4-10 cm). All patients underwent percutaneous aspiration of the liver cyst under ultrasound guidance followed by instillation of polidocanol (3%, 4-10 ml). The patients were followed up at 1, 3 and 12 months. The disappearance of the cyst or reduction in volume more than 90% was considered successful. If the fluid was accumulated at 1month the procedure was repeated. If after the second injection the fluid accumulation was more than 50% of the initial volume the case was considered a failure and a laparoscopic deroofing was performed.. The procedure was successful in 10 patients, 9 after the first instillation and one after the second (76.9%). The mean initial volume of cysts was 228 ml, and the mean reduction in volume at 1, 3 and 12 months was 80.2%, 91.9% and 96.7%. The cyst resolution was gradual with clinically significant cyst reduction achievement within 1 year after therapy. In 3 patients the fluid reaccumulated at the same volume despite 2 instillations. Those 3 cases the procedure was considered failure and the patients were sent to surgery. In 2 patients (one successfully treated and one with treatment failure) bleeding during the first puncture and aspiration appeared and the therapy was postponed for 1 month. There were no significant adverse effects, and all the patients had relief of symptoms after therapy.. This initial experience with percutaneous aspiration and polidocanol sclerosis of hepatic cysts demonstrated that the technique is efficient and safe.

Topics: Adult; Aged; Cysts; Female; Humans; Liver Diseases; Male; Middle Aged; Polidocanol; Polyethylene Glycols; Prospective Studies; Sclerosing Solutions; Sclerotherapy; Suction; Ultrasonography, Interventional

Hepatic bleeding following abdominal trauma is a serious problem. The implementation of various materials and techniques have been attempted to prevent bleeding but a standard method is indefinite.. Hepatic resection model was performed on rats. The efficacy of hemostasis with Polidocanol and Tetradecyl Sulfate has been evaluated through the comparison of perioperative bleeding amount and preoperative and postoperative hematocrit levels in the 24th hour. Also, histopathologic changes on parenchyma have been compared at a microscopic level.. Preoperative and postoperative hematocrit differences were 5.50 +/- 0.59 in Polidocanol group and 10 +/- 1.30 in Tetradecyl Sulfate group (MW: 2, p < 0.001). Perioperative bleeding amounts were: 1.50 +/- 0.20 mL in the Polidocanol group, 3.50 +/- 0.15 mL in the Tetradecyl Sulfate group and 7.50 +/- 0.41 mL in the Control Group. Upon comparison of perioperative bleeding amounts: the Control Group values were very high in comparison to the Polidocanol group (p < 0.001) and the Tetradecyl Sulfate group values were higher than those of the Polidocanol group (p < 0.05).. Local sclerosing agents, especially Polidocanol, appear to be an effective alternative method in hemostasis of hepatic bleeding.

Topics: Animals; Female; Hemorrhage; Hemostasis; Liver Diseases; Polidocanol; Polyethylene Glycols; Rats; Rats, Wistar; Sclerosing Solutions; Sodium Tetradecyl Sulfate

First experiences are reported with percutaneous sclerosing therapy of cysts with polidocanol (aethoxysklerol 1%) using ultrasound for needle guidance. They cover two patients with symptomatic cysts of the liver and a patient with polyglobulinemia and an erythropoietin-producing renal cyst. These experiences are compared to previously reported ones.

Topics: Adult; Aged; Cysts; Female; Humans; Kidney Diseases, Cystic; Liver Diseases; Male; Polidocanol; Polyethylene Glycols; Sclerosing Solutions; Ultrasonography